ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA clears expanded access IND for APT’s PhageBank therapy for Covid-19-related bacterial infections
November 23, 2020Adaptive Phage Therapeutics (APT) announced clearance by the U.S. Food and Drug Administration (FDA) of the company’s Expanded Access IND for PhageBank treatment for pneumonia or bacteremia/septicemia due to Acinetobacter baumannii, Pseudomonas ... -
FDA clears first clinical study for a polymicrobial phage library-based treatment for antibiotic-resistant infections
March 17, 2020Adaptive Phage Therapeutics (APT) said that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of PhageBank.
Pharma Sources Insight January 2025
